{"id":10751,"date":"2026-02-17T01:13:25","date_gmt":"2026-02-17T01:13:25","guid":{"rendered":"https:\/\/pharmamachinecn.com\/?p=10751"},"modified":"2026-03-18T03:12:56","modified_gmt":"2026-03-18T03:12:56","slug":"new-drug-application-in-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pharmamachinecn.com\/tr\/new-drug-application-in-pharmaceuticals\/","title":{"rendered":"\u0130la\u00e7 Sekt\u00f6r\u00fcnde Yeni \u0130la\u00e7 Ba\u015fvurusu (NDA): Bilmeniz Gereken Her \u015eey"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10751\" class=\"elementor elementor-10751\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-656075b4 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"656075b4\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-78348194\" data-id=\"78348194\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2b902b66 product-data-tab elementor-widget elementor-widget-text-editor\" data-id=\"2b902b66\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u0130la\u00e7 \u015firketlerinin en b\u00fcy\u00fck bask\u0131y\u0131 hissetti\u011fi a\u015fama genellikle Yeni \u0130la\u00e7 Ba\u015fvurusu (NDA) a\u015famas\u0131d\u0131r. Bu a\u015famada, y\u0131llarca s\u00fcren geli\u015ftirme, test ve yat\u0131r\u0131mlar FDA taraf\u0131ndan resmen incelenir.<\/p><p>Basit\u00e7e ifade etmek gerekirse, ila\u00e7 sekt\u00f6r\u00fcnde NDA (Yeni \u0130la\u00e7 Ba\u015fvurusu), bir \u015firketin yeni bir ila\u00e7 i\u00e7in onay talebinde bulunmak \u00fczere FDA&#039;ya (ABD G\u0131da ve \u0130la\u00e7 \u0130daresi) sundu\u011fu belgedir. Bu, herhangi bir ila\u00e7 geli\u015ftirme s\u00fcrecinde \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131d\u0131r.<\/p><p>Dolay\u0131s\u0131yla, yeni bir form\u00fclasyon geli\u015ftiriyorsan\u0131z veya \u00fcretimi \u00f6l\u00e7eklendirmeye haz\u0131rlan\u0131yorsan\u0131z, NDA ba\u015fvuru s\u00fcrecinin nas\u0131l i\u015fledi\u011fini anlaman\u0131z gerekiyor. Ve bug\u00fcn tam olarak buna odaklanaca\u011f\u0131z. Hadi ba\u015flayal\u0131m.<\/p><h2><strong><b>\u0130la\u00e7 sekt\u00f6r\u00fcnde NDA nedir?<\/b><\/strong><\/h2><figure id=\"attachment_10754\" aria-describedby=\"caption-attachment-10754\" style=\"width: 624px\" class=\"wp-caption aligncenter\"><img fetchpriority=\"high\" decoding=\"async\" class=\"size-full wp-image-10754\" src=\"https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2025\/12\/The-FDA-headquarters.png\" alt=\"FDA genel merkezi\" width=\"624\" height=\"351\" srcset=\"https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2025\/12\/The-FDA-headquarters.png 624w, https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2025\/12\/The-FDA-headquarters-300x169.png 300w, https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2025\/12\/The-FDA-headquarters-18x10.png 18w, https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2025\/12\/The-FDA-headquarters-600x338.png 600w\" sizes=\"(max-width: 624px) 100vw, 624px\" \/><figcaption id=\"caption-attachment-10754\" class=\"wp-caption-text\"><em><strong>FDA genel merkezi.<\/strong><\/em><\/figcaption><\/figure><p>NDA, resmi bir talep anlam\u0131na gelir. <a href=\"https:\/\/pharmamachinecn.com\/tr\/pharmacy-industry\/\"><u>ila\u00e7 \u015firketi<\/u><\/a>\u00a0Yeni bir ilac\u0131n piyasaya s\u00fcr\u00fclmesi i\u00e7in FDA&#039;ya onay ba\u015fvurusu yap\u0131l\u0131r. Bu, ila\u00e7 geli\u015ftirme s\u00fcrecinin son ad\u0131m\u0131d\u0131r ve FDA&#039;n\u0131n ilac\u0131n g\u00fcvenli ve faydal\u0131 olup olmad\u0131\u011f\u0131na karar vermesi i\u00e7in gereken her \u015feyi i\u00e7erir.<\/p><p>Ancak s\u00fcre\u00e7 olduk\u00e7a zahmetli. Bu y\u00fczden sadece <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9293739\/\" target=\"_blank\" rel=\"noopener\"><u>her 10 ila\u00e7tan yakla\u015f\u0131k 1&#039;i<\/u><\/a>\u00a0Klinik denemelere girenlerin ne kadar\u0131 onay a\u015famas\u0131na kadar ula\u015fabiliyor? Bu say\u0131, yolun zorluklar\u0131n\u0131 ve NDA&#039;n\u0131n oynad\u0131\u011f\u0131 \u00f6nemli rol\u00fc g\u00f6stermektedir.<\/p><p>Gizlilik s\u00f6zle\u015fmesi (NDA) tam bir anla\u015fma gibi i\u015flev g\u00f6r\u00fcr. <strong>\u201c&quot;hikaye&quot;\u201d<\/strong> \u0130lac\u0131n i\u00e7eri\u011fi \u015f\u00f6yledir:<\/p><ul><li>T\u00fcm klinik ara\u015ft\u0131rma sonu\u00e7lar\u0131<\/li><li>G\u00fcvenlik ve etkinlik hakk\u0131nda eksiksiz veriler.<\/li><li>\u0130lac\u0131n nas\u0131l \u00fcretildi\u011fine dair detaylar<\/li><li>Kalite kontrol ve stabilite bilgileri<\/li><li>Ambalajlama, etiketleme ve \u00f6nerilen kullan\u0131m talimatlar\u0131<\/li><\/ul><p>FDA, faydalar\u0131n risklerden daha a\u011f\u0131r bast\u0131\u011f\u0131n\u0131 do\u011frulamak i\u00e7in bu bilgileri inceler. Dahas\u0131, bu inceleme, \u00fcretim s\u00fcrecinin s\u00fcrekli olarak g\u00fcvenli ve g\u00fcvenilir bir \u00fcr\u00fcn \u00fcretebildi\u011fini kan\u0131tlar.<\/p><h2><strong><b>\u0130la\u00e7 Sekt\u00f6r\u00fcnde NDA&#039;n\u0131n Amac\u0131<\/b><\/strong><\/h2><p>Yeni ila\u00e7 ba\u015fvurusunun (NDA) temel amac\u0131, yeni bir ilac\u0131n g\u00fcvenli, etkili ve s\u00fcrekli olarak y\u00fcksek kalitede \u00fcretildi\u011fini g\u00f6stermektir.<\/p><p>FDA, bu uygulamay\u0131 \u00fcr\u00fcn\u00fcn klinik verilerinden \u00fcretim s\u00fcrecine kadar her par\u00e7as\u0131n\u0131n kat\u0131 standartlar\u0131 kar\u015f\u0131lad\u0131\u011f\u0131n\u0131 do\u011frulamak i\u00e7in kullan\u0131r. Bu gereklili\u011fin en b\u00fcy\u00fck nedenlerinden biri de sorunlar\u0131 erken tespit etmektir.<\/p><p>NDA&#039;n\u0131n (Yeni \u0130la\u00e7 Ba\u015fvuru Formu) amac\u0131, hastalar\u0131 tutars\u0131z veya g\u00fcvenli olmayan \u00fcr\u00fcnlerden korumakt\u0131r. Bu form, FDA&#039;ya ilac\u0131n nas\u0131l \u00fcretildi\u011fine ve g\u00fcvenli olup olmad\u0131\u011f\u0131na dair net bir bak\u0131\u015f a\u00e7\u0131s\u0131 sa\u011flar. <a href=\"https:\/\/pharmamachinecn.com\/tr\/pharmaceutical-equipment-list\/\"><u>ila\u00e7 ekipman\u0131<\/u><\/a>\u00a0ve bunun ard\u0131ndaki s\u00fcre\u00e7ler, her partide ayn\u0131 kaliteyi sa\u011flayabilir.<\/p><h2><strong><b>Gizlilik S\u00f6zle\u015fmesinin Temel Bile\u015fenleri<\/b><\/strong><\/h2><p>\u0130la\u00e7 sekt\u00f6r\u00fcndeki bir NDA (Yeni \u0130la\u00e7 Ba\u015fvurusu), FDA&#039;ya bir ilac\u0131n nas\u0131l performans g\u00f6sterdi\u011fine dair kapsaml\u0131 bir tablo sunan \u00e7e\u015fitli \u00f6nemli b\u00f6l\u00fcmler i\u00e7erir. Bu gereksinimi kar\u015f\u0131lamak istiyorsan\u0131z bilmeniz gereken bile\u015fenler \u015funlard\u0131r:.<\/p><h3><strong><b>1. Klinik Veri Paketi<\/b><\/strong><\/h3><p>Klinik veri paketi, Faz 1, 2 ve 3 \u00e7al\u0131\u015fmalar\u0131ndan elde edilen t\u00fcm sonu\u00e7lar\u0131 i\u00e7ermektedir. Bu \u00e7al\u0131\u015fmalar, ilac\u0131n insan v\u00fccudunda nas\u0131l davrand\u0131\u011f\u0131n\u0131, etkinli\u011fini ve ger\u00e7ek tedavi s\u0131ras\u0131nda ortaya \u00e7\u0131kabilecek potansiyel riskleri g\u00f6stermektedir.<\/p><p>Bu b\u00f6l\u00fcmde ayr\u0131ca yeni form\u00fclasyon nedeniyle meydana gelen t\u00fcm olumsuz olaylara ili\u015fkin g\u00fcvenlik de\u011ferlendirmeleri ve ayr\u0131nt\u0131l\u0131 raporlar yer almaktad\u0131r.<\/p><h3><strong><b>2. CMC (Kimya, \u00dcretim ve Kontroller)<\/b><\/strong><\/h3><p>CMC, bir NDA&#039;n\u0131n en \u00f6nemli k\u0131s\u0131mlar\u0131ndan biridir \u00e7\u00fcnk\u00fc ilac\u0131n tam olarak nas\u0131l \u00fcretildi\u011fini a\u00e7\u0131klar. \u0130la\u00e7 \u00fcretimiyle ilgili bilgileri kapsar. <a href=\"https:\/\/pharmamachinecn.com\/tr\/api-in-pharmaceutical-industry-explained\/\"><u>aktif farmas\u00f6tik bile\u015fen (API)<\/u><\/a>, Kalite standartlar\u0131 da dahil olmak \u00fczere.<\/p><p>Dahas\u0131, bu bile\u015fen, ham maddelerden nihai \u00fcr\u00fcne kadar \u00fcretim s\u00fcrecini tan\u0131mlar. Bu bilgilerle FDA, ilac\u0131n b\u00fcy\u00fck \u00f6l\u00e7eklerde tutarl\u0131 ve g\u00fcvenli bir \u015fekilde \u00fcretilip \u00fcretilemeyece\u011fini belirleyebilir.<\/p><h3><strong><b>3. Etiketleme ve Ambalajlama<\/b><\/strong><\/h3><p>Bu b\u00f6l\u00fcmde, \u00f6nerilen ila\u00e7 etiketi ve \u00fcr\u00fcnle birlikte verilecek t\u00fcm talimatlar \u00f6zetlenmi\u015ftir. Bunlar aras\u0131nda dozaj k\u0131lavuzlar\u0131, kullan\u0131m talimatlar\u0131, uyar\u0131lar ve g\u00fcvenlik bilgileri yer almaktad\u0131r.<\/p><p>A\u00e7\u0131k etiketleme ve <a href=\"https:\/\/pharmamachinecn.com\/tr\/pharmaceutical-serialization-track-and-trace\/\"><u>serile\u015ftirme<\/u><\/a>\u00a0Bu bilgiler hasta g\u00fcvenli\u011fi i\u00e7in hayati \u00f6nem ta\u015f\u0131r ve sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131n\u0131n ilac\u0131 nas\u0131l uygulayacaklar\u0131n\u0131 tam olarak bilmelerini garanti eder. FDA, i\u00e7eri\u011fin do\u011fru oldu\u011fundan emin olmak i\u00e7in dikkatlice inceler.<\/p><h3><strong><b>4. \u0130dari ve Yasal Gereklilikler<\/b><\/strong><\/h3><p>\u0130la\u00e7 end\u00fcstrisindeki bir NDA&#039;n\u0131n son b\u00f6l\u00fcm\u00fc, \u00f6nemli yasal ve idari belgeleri kapsar. Bu a\u015famada, hasta sertifikalar\u0131, kullan\u0131c\u0131 \u00fccreti \u00f6demelerinin kan\u0131t\u0131 ve di\u011fer gerekli d\u00fczenleyici belgeleri sa\u011flaman\u0131z gerekmektedir.<\/p><p>Ayr\u0131ca, \u015firketin t\u00fcm FDA ve yasal y\u00fck\u00fcml\u00fcl\u00fcklerini yerine getirdi\u011fini teyit eden uyumluluk formlar\u0131n\u0131 da i\u00e7erir.<\/p><h2><strong><b>Gizlilik S\u00f6zle\u015fmesi (NDA) Ba\u015fvuru S\u00fcreci Nas\u0131l \u0130\u015fliyor?<\/b><\/strong><\/h2><p><img decoding=\"async\" class=\"wp-image-10753 size-full\" src=\"https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2026\/02\/NDA-in-Pharmaceuticals.jpg\" alt=\"NDA ba\u015fvuru s\u00fcreci\" width=\"1000\" height=\"800\" srcset=\"https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2026\/02\/NDA-in-Pharmaceuticals.jpg 1000w, https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2026\/02\/NDA-in-Pharmaceuticals-300x240.jpg 300w, https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2026\/02\/NDA-in-Pharmaceuticals-768x614.jpg 768w, https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2026\/02\/NDA-in-Pharmaceuticals-15x12.jpg 15w, https:\/\/pharmamachinecn.com\/wp-content\/uploads\/2026\/02\/NDA-in-Pharmaceuticals-600x480.jpg 600w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p><p>Yeni ila\u00e7 ba\u015fvuru dosyas\u0131 sunmak, FDA&#039;n\u0131n eksiksiz, do\u011fru ve y\u00fcksek kaliteli bilgi almas\u0131n\u0131 garanti etmeye yard\u0131mc\u0131 olan yap\u0131land\u0131r\u0131lm\u0131\u015f bir s\u00fcre\u00e7tir.<\/p><p>\u0130\u015fte mevzuata uygun olmak i\u00e7in izlemeniz gereken ad\u0131mlar:<\/p><h3><strong><b>1. FDA ile NDA \u00d6ncesi Toplant\u0131<\/b><\/strong><\/h3><p>\u00c7o\u011fu \u015firket, NDA ba\u015fvurusu yapmadan \u00f6nce bir \u00f6n NDA toplant\u0131s\u0131 d\u00fczenler. Bu toplant\u0131, her iki tarafa da nihai klinik sonu\u00e7lar\u0131, \u00fcretim verilerini ve kalan endi\u015feleri g\u00f6zden ge\u00e7irme \u015fans\u0131 verir.<\/p><p>Bu ayn\u0131 zamanda FDA&#039;n\u0131n ba\u015fvuruda ne bekledi\u011fini netle\u015ftirmeye yard\u0131mc\u0131 olur ve bu da gelecekte gecikme riskini azalt\u0131r.<\/p><h3><strong><b>2. Eksiksiz Dok\u00fcmantasyon Paketinin Haz\u0131rlanmas\u0131<\/b><\/strong><\/h3><p>Plan onayland\u0131ktan sonra \u015firket, klinik sonu\u00e7lar, CMC bilgileri, etiketleme taslaklar\u0131 ve idari formlar da dahil olmak \u00fczere gerekli t\u00fcm verileri derler.<\/p><p>Bu ad\u0131m, d\u00fczenleyici, \u00fcretim, kalite ve klinik ekipler aras\u0131nda koordinasyon gerektirir. Her zaman hat\u0131rlay\u0131n, iyi organize edilmi\u015f bir paket, sorunsuz bir inceleme \u015fans\u0131n\u0131 art\u0131r\u0131r.<\/p><h3><strong><b>3. FDA Elektronik Ge\u00e7idi Arac\u0131l\u0131\u011f\u0131yla Ba\u015fvuru<\/b><\/strong><\/h3><p>NDA ba\u015fvurusu nihayet FDA&#039;n\u0131n \u00e7evrimi\u00e7i sistemi arac\u0131l\u0131\u011f\u0131yla elektronik olarak g\u00f6nderildi. <a href=\"https:\/\/www.fda.gov\/industry\/electronic-submissions-gateway-next-generation-esg-nextgen\" target=\"_blank\" rel=\"noopener\"><u>ESG Yeni Nesil<\/u><\/a>. Dosyan\u0131n FDA taraf\u0131ndan i\u015flenip incelenebilmesi i\u00e7in kat\u0131 bi\u00e7imlendirme kurallar\u0131na uymas\u0131na dikkat edin. Ba\u015fvuru g\u00f6nderildikten sonra, FDA&#039;n\u0131n dahili inceleme s\u00fcrecine girer.<\/p><h3><strong><b>4. FDA&#039;n\u0131n Detayl\u0131 \u0130ncelemesi <\/b><\/strong><\/h3><p>\u0130nceleme dosyas\u0131 sunulduktan sonra, FDA t\u00fcm verilerin ayr\u0131nt\u0131l\u0131 bir de\u011ferlendirmesine ba\u015flar. \u0130nceleyiciler klinik performans\u0131, \u00fcretim kalitesini, g\u00fcvenlik bilgilerini ve etiketleme do\u011frulu\u011funu de\u011ferlendirir.<\/p><p>Bu a\u015famada FDA s\u0131kl\u0131kla sorular veya a\u00e7\u0131klama talepleri g\u00f6nderir. \u015eirketler gecikmeleri \u00f6nlemek i\u00e7in h\u0131zl\u0131 ve net bir \u015fekilde yan\u0131t vermelidir.<\/p><h3><strong><b>5. Nihai Karar ve Onay<\/b><\/strong><\/h3><p>Veriler g\u00fcvenlik, etkinlik ve \u00fcretim tutarl\u0131l\u0131\u011f\u0131n\u0131 destekliyorsa, FDA onay mektubu yay\u0131nlar. Ancak, FDA \u00f6nemli sorunlar tespit ederse, kurum bir ret karar\u0131 verebilir. <a href=\"https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-314\/subpart-D\/section-314.110\" target=\"_blank\" rel=\"noopener\"><u>Tam Yan\u0131t Mektubu<\/u><\/a>\u00a0D\u00fczeltilmesi gereken noktalar\u0131 \u00f6zetliyor.<\/p><p>De\u011fi\u015fiklikleri yapt\u0131ktan ve onay ald\u0131ktan sonra, \u00fcr\u00fcn\u00fcn\u00fcz art\u0131k ABD&#039;de pazarlanabilir demektir.<\/p><h2><strong><b>NDA onay s\u00fcreci ne kadar s\u00fcrer?<\/b><\/strong><\/h2><p>Yeni ila\u00e7 ba\u015fvurusunun onay s\u00fcreci, ilac\u0131n ald\u0131\u011f\u0131 de\u011ferlendirme t\u00fcr\u00fcne ba\u011fl\u0131d\u0131r. \u00c7o\u011fu \u00fcr\u00fcn i\u00e7in FDA, ba\u015fvurunun kabul edilmesinden itibaren genellikle 10 ila 12 ay s\u00fcren standart bir de\u011ferlendirme s\u00fcreci izler.<\/p><p>Baz\u0131 durumlarda bir ila\u00e7 \u00f6ncelikli incelemeye hak kazansa da, bu durumda onay s\u00fcresi yakla\u015f\u0131k 6 aya kadar neredeyse yar\u0131 yar\u0131ya k\u0131sal\u0131r. \u00d6ncelikli inceleme yaln\u0131zca tedavide \u00f6nemli iyile\u015ftirmeler sa\u011flayan veya ciddi t\u0131bbi ihtiya\u00e7lar\u0131 kar\u015f\u0131layan ila\u00e7lara verilir.<\/p><h2><strong><b>SSS<\/b><\/strong><\/h2><h3><strong><b>1. <\/b><\/strong><strong><b>Gizlilik s\u00f6zle\u015fmesi incelemesi s\u0131ras\u0131nda tescilli veya gizli bilgiler nas\u0131l korunur?<\/b><\/strong><\/h3><p>FDA, bir NDA&#039;daki klinik ve CMC verilerinin b\u00fcy\u00fck bir k\u0131sm\u0131n\u0131 gizli ticari bilgi olarak de\u011ferlendirir. Kamuoyuna a\u00e7\u0131k \u00f6zetler ve onaylanm\u0131\u015f etiketleme bilgileri yay\u0131nlan\u0131r, ancak ham veri k\u00fcmeleri ve tescilli \u00fcretim detaylar\u0131 yasal gizlilik h\u00fck\u00fcmleri kapsam\u0131nda korunmaya devam eder.<\/p><h3><strong><b>2. <\/b><\/strong><strong><b>Onaylanabilir mektup veya eksiksiz yan\u0131t mektubu nedir?<\/b><\/strong><\/h3><p>FDA, sunulan belgeye onay veremezse, eksiklikleri ve gerekli eylemleri a\u00e7\u0131klayan eksiksiz bir yan\u0131t mektubu yay\u0131nlar. Onaylanabilir mektup ise onaydan \u00f6nce kar\u015f\u0131lanmas\u0131 gereken ko\u015fullar\u0131 \u00f6zetler. Sponsorlar, de\u011fi\u015fiklikler, yeni veriler veya risk y\u00f6netimi \u00f6nerileriyle yan\u0131t verirler.<\/p><h3><strong><b>3. <\/b><\/strong><strong><b>Gizlilik s\u00f6zle\u015fmelerinde patentler ve m\u00fcnhas\u0131rl\u0131k ne zaman \u00f6nem kazan\u0131r?<\/b><\/strong><\/h3><p>Sponsorlar patent bilgilerini sunar ve belirli s\u00fcreler i\u00e7in jenerik ila\u00e7lar\u0131n piyasaya giri\u015fini geciktiren d\u00fczenleyici m\u00fcnhas\u0131rl\u0131klar talep edebilirler. NDA&#039;daki patent listeleri, daha sonraki jenerik ila\u00e7 ba\u015fvurular\u0131 i\u00e7in patent sertifikasyon s\u00fcre\u00e7lerini de destekler. M\u00fcnhas\u0131rl\u0131k t\u00fcrleri aras\u0131nda yeni kimyasal madde m\u00fcnhas\u0131rl\u0131\u011f\u0131, pediatrik m\u00fcnhas\u0131rl\u0131k ve yetim ila\u00e7 m\u00fcnhas\u0131rl\u0131\u011f\u0131 gibi t\u00fcrler yer almaktad\u0131r.<\/p><h2><strong><b>Yanl\u0131\u015f Makinelerle Gizlilik S\u00f6zle\u015fmenizin Elinizden Kaybolmas\u0131na \u0130zin Vermeyin<\/b><\/strong><\/h2><p>\u0130la\u00e7 end\u00fcstrisinde NDA ba\u015fvurusu yapmak \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131d\u0131r, ancak onay yaln\u0131zca klinik verilere ba\u011fl\u0131 de\u011fildir. FDA&#039;n\u0131n en \u00e7ok dikkate ald\u0131\u011f\u0131 \u015feylerden biri de kulland\u0131\u011f\u0131n\u0131z makinelerin kalitesidir. Bu da Finetech gibi g\u00fcvenilir tedarik\u00e7ilere sahip olman\u0131n \u00f6nemini g\u00f6stermektedir.<\/p><p>\u0130la\u00e7 \u00fcretim makinelerimiz, s\u00fcrecin her a\u015famas\u0131nda g\u00fcvenilir ve uyumlu \u00fcretimi desteklemek \u00fczere tasarlanm\u0131\u015ft\u0131r. Asl\u0131nda, 60&#039;tan fazla \u00fclkedeki \u00fcreticiler ve 500&#039;den fazla m\u00fc\u015fteri, FDA onay\u0131 i\u00e7in gerekli teknik temeli g\u00fc\u00e7lendiren ekipmanlar sa\u011flad\u0131\u011f\u0131m\u0131z i\u00e7in Finetech&#039;e g\u00fcveniyor.<\/p><p><em><i>Makine ar\u0131zas\u0131 nedeniyle mahsur kald\u0131ysan\u0131z, <\/i><\/em><a href=\"https:\/\/pharmamachinecn.com\/tr\/contact-us\/\"><em><u><i>Uzmanlar\u0131m\u0131zla h\u0131zl\u0131 bir g\u00f6r\u00fc\u015fme yap\u0131n.<\/i><\/u><\/em><\/a><em><i>\u00a0Bug\u00fcn!<\/i><\/em><\/p><h2><strong>Referanslar:<\/strong><\/h2><p><a href=\"https:\/\/www.ataxia.org\/all-about-new-drug-applications-ndas\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\"><em><strong>Yeni \u0130la\u00e7 Ba\u015fvurular\u0131 (NDA'lar) Hakk\u0131nda Her \u015eey<\/strong><\/em><\/span><\/a><\/p><p><a href=\"https:\/\/synergbiopharma.com\/blog\/nda-vs-anda\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\"><em><strong>NDA ve ANDA i\u00e7in Eksiksiz K\u0131lavuz: Farkl\u0131l\u0131klar, S\u00fcre\u00e7ler ve Gereklilikler<\/strong><\/em><\/span><\/a>.<\/p><p><a href=\"https:\/\/synapse.patsnap.com\/article\/what-is-an-nda-new-drug-application-and-how-does-it-differ-from-bla\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\"><strong><em>NDA (Yeni \u0130la\u00e7 Ba\u015fvurusu) Nedir ve BLA'dan Fark\u0131 Nedir?<\/em><\/strong><\/span><\/a><\/p><p><a href=\"https:\/\/toolkit.ncats.nih.gov\/glossary\/new-drug-application\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\"><em><strong>Yeni \u0130la\u00e7 Ba\u015fvurusu<\/strong><\/em><\/span><\/a>.<\/p><h2><b>Telif Hakk\u0131 Uyar\u0131s\u0131:\u00a0<\/b><\/h2><p>Finetech Group'un \u00f6nceden a\u00e7\u0131k yaz\u0131l\u0131 onay\u0131 olmadan bu web sitesindeki herhangi bir i\u00e7eri\u011fi \u00e7o\u011faltamaz, de\u011fi\u015ftiremez, yay\u0131nlayamaz, g\u00f6r\u00fcnt\u00fcleyemez, iletemez veya herhangi bir \u015fekilde istismar edemezsiniz veya bu t\u00fcr i\u00e7eri\u011fi herhangi bir veritaban\u0131 olu\u015fturmak i\u00e7in kullanamazs\u0131n\u0131z. \u0130\u00e7eri\u011fi kullanma izni i\u00e7in l\u00fctfen ileti\u015fime ge\u00e7in: <a href=\"mailto:info@pharmamachinecn.com\"><span style=\"text-decoration: underline;\">info@pharmamachinecn.com<\/span><\/a><\/p><h2><b>Yasal Uyar\u0131:<\/b><\/h2><p>Bu makalede yer alan bilgiler yaln\u0131zca genel bilgilendirme ama\u00e7l\u0131d\u0131r. \u015eirket, herhangi bir bilginin do\u011frulu\u011funu, g\u00fcncelli\u011fini veya eksiksizli\u011fini garanti etmez ve \u015eirket, bu makalenin i\u00e7eri\u011findeki hatalar veya eksiklikler i\u00e7in hi\u00e7bir sorumluluk kabul etmez.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>The NDA (New Drug Application) stage is often where pharma teams feel the most pressure. It\u2019s the point where years [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10753,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[61],"tags":[],"class_list":["post-10751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-technology"],"acf":[],"_links":{"self":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts\/10751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/comments?post=10751"}],"version-history":[{"count":16,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts\/10751\/revisions"}],"predecessor-version":[{"id":13325,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts\/10751\/revisions\/13325"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/media\/10753"}],"wp:attachment":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/media?parent=10751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/categories?post=10751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/tags?post=10751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}